FIGURE 2 from Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity
Year: 2023
Type: other
Abstract: Systemic tumor regression sustained by combining TAA-specific T cells and Delta-24-RGDOX in localized intratumoral treatment. A, A cartoon depiction of the treatment scheme for schedule (left) and positions of tumor implantation, T-cell and virus injection (right). s.c.: subcutaneously; i.t.: intratumorally. B, Spaghetti plots of the volume of the tumors from the indicated treatment groups. C, Survival plots of the treatment groups. n = 10 except n = 8 for PBS. D, The cell lysates from the indicated cell lines or tumors were analyzed with immunoblotting for OVA (the target of OT-I cells) or gp100. Note that the tumors from PBS or RGDOX group were treated ones collected 8 days after OT-I cell injection; the tumors from OT-I cells group were relapsed tumors collected 32 days after OT-I cell injection. The numbers on the bottom represent relative expression levels of gp100 and OVA normalized against GAPGH. E and F, Survival plots for survivors from combination treatment after being first rechallenged with B16-OVA (D; naïve: n = 4; survivor: n = 6) and then CMT64 (E; naïve: n = 5; survivor: n = 6) cells. RGDOX: Delta-24-RGDOX. ns, not significant (P > 0.05); *, P < 0.05; **, P < 0.01. log-rank test.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4382240741